Home Health Parametric Portfolio Associates LLC Increases Position in Five Prime Therapeutics Inc (FPRX)

Parametric Portfolio Associates LLC Increases Position in Five Prime Therapeutics Inc (FPRX)

8
0
SHARE


Parametric Portfolio Associates LLC boosted its position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 140.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,894 shares of the biotechnology company’s stock after acquiring an additional 13,977 shares during the quarter. Parametric Portfolio Associates LLC owned 0.09% of Five Prime Therapeutics worth $719,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of FPRX. Creative Planning increased its position in Five Prime Therapeutics by 0.8% during the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 54 shares during the last quarter. Legal & General Group Plc increased its position in Five Prime Therapeutics by 3.1% during the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 287 shares during the last quarter. Essex Investment Management Co. LLC increased its position in Five Prime Therapeutics by 22.2% during the second quarter. Essex Investment Management Co. LLC now owns 12,692 shares of the biotechnology company’s stock valued at $382,000 after acquiring an additional 2,308 shares during the last quarter. Ark Investment Management LLC grew its holdings in Five Prime Therapeutics by 299.2% during the second quarter. Ark Investment Management LLC now owns 14,174 shares of the biotechnology company’s stock valued at $427,000 after purchasing an additional 10,623 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in Five Prime Therapeutics during the second quarter valued at about $602,000. Institutional investors own 83.80% of the company’s stock.

In other news, Director William R. Ringo sold 1,800 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now owns 1,200 shares of the company’s stock, valued at $48,312. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director William R. Ringo sold 2,000 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $76,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,400 shares of company stock valued at $175,666. Corporate insiders own 6.50% of the company’s stock.

Several research firms have issued reports on FPRX. Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. ValuEngine lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. BMO Capital Markets boosted their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. Royal Bank Of Canada boosted their price target on Five Prime Therapeutics from $41.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, November 6th. Finally, Jefferies Group reissued a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $64.00.

Five Prime Therapeutics Inc (NASDAQ:FPRX) traded down $0.50 during midday trading on Thursday, hitting $23.14. The stock had a trading volume of 572,945 shares, compared to its average volume of 407,067. Five Prime Therapeutics Inc has a 1 year low of $21.41 and a 1 year high of $55.42.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). The business had revenue of $8.33 million during the quarter, compared to the consensus estimate of $16.16 million. Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the company earned ($0.72) EPS. research analysts forecast that Five Prime Therapeutics Inc will post -5.56 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Parametric Portfolio Associates LLC Increases Position in Five Prime Therapeutics Inc (FPRX)” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://weekherald.com/2017/12/07/parametric-portfolio-associates-llc-purchases-13977-shares-of-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)




Receive News & Ratings for Five Prime Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Five Prime Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.



Sumber berita :

https://weekherald.com/2017/12/07/parametric-portfolio-associates-llc-purchases-13977-shares-of-five-prime-therapeutics-inc-fprx.html